Teva says anti-IL-15 drug meets primary endpoint in Phase 2a celiac disease trial
TEVA•Teva said its anti-IL-15 drug met the primary endpoint in a Phase 2a celiac disease trial, with a Phase 2b study expected in the second half of 2027. The company also outlined pipeline plans and a target of $6–7 billion in innovative medicines revenue by 2030.
1. Celiac disease trial
Teva said its anti-IL-15 drug met the primary endpoint in a Phase 2a celiac disease trial. A Phase 2b study is expected in the second half of 2027.
2. Pipeline plans
Teva said TEV-'408 is advancing to a Phase 2/3 vitiligo study after encouraging Phase 1b results. Its ATTENUKINE anti-PD-1/IL-2 program has shown early efficacy signals and a favorable safety profile in an ongoing Phase 1 trial in advanced cancer. Teva is targeting $6–7 billion in innovative medicines revenue by 2030 and says its pipeline could support one innovative medicine launch annually through 2030, with more than $10 billion in combined peak sales potential.
